Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Natanael Cordeiro

Physician Assistant Fall River, MA Physician Assistant

NPI 1740531730 CMS profile 11237198

101 Jeremiah V Sullivan Dr, Fall River, MA 02721

Open in the dashboard

General payments

$2,869

132 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Natanael Cordeiro of Fall River, MA is reported in the CMS Open Payments database as having received $2,869 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $672 25
2024 General $851 37
2023 General $495 24
2022 General $597 32
2021 General $255 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Natanael Cordeiro
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Natanael Cordeiro were reported at $672. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Natanael Cordeiro Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $255 $132 $37–$438 $132
2022 $597 $155 $48–$522 $149
2023 $495 $167 $52–$557 $160
2024 $851 $178 $55–$600 $164
2025 $672 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $735 30 payments
  2. Novo Nordisk Inc $381 19 payments
  3. Lilly USA, LLC $254 11 payments
  4. AbbVie, Inc. $217 9 payments
  5. Abbott Laboratories $148 7 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $134 8 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $129 7 payments
  8. Indivior Inc. $100 4 payments
  9. Exact Sciences Corporation $100 4 payments
  10. Otsuka America Pharmaceutical, Inc. $90 4 payments
  11. Other $581 29 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,849 131 payments
  2. Education $20 1 payment
Products named General payments · program years 2021–2025
  1. FARXIGA $374 15 payments
  2. AIRSUPRA $218 7 payments
  3. BREZTRI $206 9 payments
  4. Ozempic $194 10 payments
  5. MOUNJARO $171 7 payments
  6. FreeStyle Libre 3 $148 7 payments
  7. RYBELSUS $144 8 payments
  8. ZEPBOUND $135 6 payments
  9. Kerendia $134 8 payments
  10. XIFAXAN $129 7 payments
  11. Other $1,394 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

2,266

Median for Physician Assistant: 241

Drug cost

$124,839

Median for Physician Assistant: $4,110

Branded share of claims

21.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 34 $28,507
Ozempic Semaglutide Brand 21 $20,007
Vivitrol Naltrexone Microspheres Brand 12 $19,376
Jardiance Empagliflozin Brand 13 $17,463
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 54 $8,868
Tradjenta Linagliptin Brand 12 $8,086
Albuterol Sulfate Hfa Albuterol Sulfate Brand 76 $2,091
Doxycycline Monohydrate Generic 113 $1,182
Atorvastatin Calcium Generic 104 $1,031
Methylprednisolone Generic 126 $917

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$138,725

Of which drugs: $3,556

Medicare patients

660

Average age 74

Services billed

3,806

338 women, 322 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 44%
Diabetes 25%
Ischemic heart disease 23%
Chronic kidney disease 20%
Osteoporosis 19%
Atrial fibrillation 18%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 39 39 $3,191
Injection, methylprednisolone acetate, 1 mg J1010 Office 15 968 $94
Injection, ketorolac tromethamine, per 15 mg J1885 Office 25 102 $48

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $126
$126 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $107
$107 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $50
  • Lundbeck LLC $49
$99 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $74
$74 — —
ZEPBOUND
  • Lilly USA, LLC $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record